Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4AU8K)

Drug Name
PX-478 Drug Info
Synonyms
PX-478; 685898-44-6; PX-478 2HCl; UNII-T23U22X160; PX478; PX 478; Melphalan N-Oxide Impurity HCl; T23U22X160; 4-[Bis(2-chloroethyl)oxidoamino]-L-phenylalanine; PX-478 dihydrochloride; SCHEMBL18548830; C13H18Cl2N2O3.2ClH; DTXSID00218688; MolPort-035-789-733; 2675AH; s7612; 2-Amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; AKOS030231369; CS-5164; HY-10231; KB-80169; Z-3209; L-Phenylalanine, 4-(bis(2-chloroethyl)oxidoamino)-, dihydrochloride; (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide di
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Therapeutic Class
Anticancer Agents
Cross-matching ID
PubChem CID
11234794
CAS Number
CAS 685898-44-6
TTD Drug ID
DM4AU8K

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Hypoxia-inducible factor 1 alpha (HIF-1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
HIF-1alpha DM4OQRD Lymphoma 2A80-2A86 Phase 4 [3]
IT-101 DMNDGWE Solid tumour/cancer 2A00-2F9Z Phase 3 [4]
2-Methoxyestradiol DMGBPME Pulmonary arterial hypertension BB01.0 Phase 2 [5]
EZN-2968 DM2NBC7 Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
ENMD-1198 DM9BJ3G Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
Pyrrolidine carboxamide derivative 1 DMJK98Z N. A. N. A. Patented [8]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Hypoxia-inducible factor 1 alpha (HIF-1A) TTQHWNA HIF1A_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT00522652) Phase I Trial of PX-478. U.S. National Institutes of Health.
2 The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther. 2009 Apr;8(4):947-58.
3 A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther. 2008 Nov;7(11):3598-608.
4 CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer. Breast Cancer Res Treat. 2015 Apr;150(3):559-67.
5 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squam... Clin Cancer Res. 2004 Dec 15;10(24):8665-73.
6 Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1), in patients with refractory solid tumors.Cancer Chemother Pharmacol.2014 Feb;73(2):343-8.
7 ENMD-1198, a new analogue of 2-methoxyestradiol, displays both antiangiogenic and vascular-disrupting properties. Mol Cancer Ther. 2010 May;9(5):1408-18.
8 Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.